Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

[1]  M. Fukuoka,et al.  A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[2]  A. Wotherspoon,et al.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial , 2013, The Lancet. Oncology.

[3]  Galina Kurteva,et al.  Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. , 2013, The Lancet. Oncology.

[4]  H. Imamura,et al.  Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer , 2012, Clinical Cancer Research.

[5]  J. Thigpen.  Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone , 2012 .

[6]  A. Hinke,et al.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.

[7]  R. Kerbel,et al.  Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile , 2011, Cancer biology & therapy.

[8]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[9]  M. Frómeta,et al.  Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck , 2010, Cancer biology & therapy.

[10]  U. Krengel,et al.  Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. , 2009, Cancer research.

[11]  Yoon-Koo Kang,et al.  Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Y. Jeon,et al.  EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number , 2008, Histopathology.

[13]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[14]  M. Fukuoka,et al.  Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status , 2008, British Journal of Cancer.

[15]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[16]  Y. Kodera,et al.  A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). , 2007, Anticancer research.

[17]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Lage,et al.  Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial , 2006, Cancer biology & therapy.

[20]  T. Yoshino,et al.  Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer , 2006, Gastric Cancer.

[21]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[22]  J. Koropatnick,et al.  Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Choi,et al.  Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. , 2004, Japanese journal of clinical oncology.

[24]  Suk Woo Nam,et al.  BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.

[25]  M. Solano,et al.  Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer , 2003, Journal of immunotherapy.

[26]  J. Rak,et al.  Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibody , 2002, International journal of cancer.

[27]  U. Haglund,et al.  Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[29]  U. Haglund,et al.  Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.